Logo image of ASRT

ASSERTIO HOLDINGS INC (ASRT) Stock Price, Quote, News and Overview

NASDAQ:ASRT - Nasdaq - US04546C2052 - Common Stock - Currency: USD

0.8113  +0.01 (+0.81%)

ASRT Quote, Performance and Key Statistics

ASSERTIO HOLDINGS INC

NASDAQ:ASRT (2/6/2025, 12:49:50 PM)

0.8113

+0.01 (+0.81%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High1.8
52 Week Low0.73
Market Cap77.46M
Shares95.48M
Float92.85M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO02-12 1997-02-12


ASRT short term performance overview.The bars show the price performance of ASRT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20 -25

ASRT long term performance overview.The bars show the price performance of ASRT in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40 -60 -80

The current stock price of ASRT is 0.8113 USD. In the past month the price decreased by -8.52%. In the past year, price increased by 0.49%.

ASSERTIO HOLDINGS INC / ASRT Daily stock chart

ASRT Latest News, Press Releases and Analysis

News Image
a month ago - Assertio Holdings, Inc.

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with...

News Image
2 months ago - Assertio Holdings, Inc.

Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with...

News Image
2 months ago - Assertio Holdings, Inc.

Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study

Same-day dosing results comparable to next day dosing schedules...

News Image
2 months ago - Assertio Holdings, Inc.

Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

CTO Role to Focus on Growth from New Market and Revenue Strategies...

News Image
3 months ago - Assertio Holdings, Inc.

Assertio Reports Third Quarter 2024 Financial Results

Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million  Cash and Short-Term Investments of $88.6 Million...

ASRT Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 85.37 824.17B
NVO NOVO-NORDISK A/S-SPONS ADR 27.23 386.96B
JNJ JOHNSON & JOHNSON 15.41 370.70B
AZN ASTRAZENECA PLC-SPONS ADR 19.3 228.03B
MRK MERCK & CO. INC. 11.68 225.67B
NVS NOVARTIS AG-SPONSORED ADR 13.56 214.74B
PFE PFIZER INC 8.36 147.40B
SNY SANOFI-ADR 13.43 134.70B
BMY BRISTOL-MYERS SQUIBB CO 49.95 118.54B
ZTS ZOETIS INC 30.39 78.98B
GSK GSK PLC-SPON ADR 7.97 75.48B
TAK TAKEDA PHARMACEUTIC-SP ADR 30.92 43.13B

About ASRT

Company Profile

ASRT logo image Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The company is headquartered in Lake Forest, Illinois and currently employs 53 full-time employees. The firm has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).

Company Info

ASSERTIO HOLDINGS INC

100 S. Saunders Road, Suite 300

Lake Forest ILLINOIS 60045 US

CEO: Daniel A. Peisert

Employees: 53

Company Website: https://www.assertiotx.com/

Investor Relations: https://investor.assertiotx.com/overview/default.aspx

Phone: 12244197106

ASRT FAQ

What is the stock price of ASRT?

The current stock price of ASRT is 0.8113 USD.


What is the symbol for ASSERTIO HOLDINGS INC stock?

The exchange symbol of ASSERTIO HOLDINGS INC is ASRT and it is listed on the Nasdaq exchange.


On which exchange is ASRT stock listed?

ASRT stock is listed on the Nasdaq exchange.


Is ASRT a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ASRT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ASRT.


Does ASRT stock pay dividends?

ASRT does not pay a dividend.


What is the Price/Earnings (PE) ratio of ASRT?

ASRT does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.73).


What is the Short Interest ratio of ASRT stock?

The outstanding short interest for ASRT is 6.5% of its float.


ASRT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ASRT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ASRT. ASRT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ASRT Financial Highlights

Over the last trailing twelve months ASRT reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS decreased by -177.66% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -24.81%
ROE -52.47%
Debt/Equity 0.3
Chartmill High Growth Momentum
EPS Q2Q%93.48%
Sales Q2Q%-18.03%
EPS 1Y (TTM)-177.66%
Revenue 1Y (TTM)-25.8%

ASRT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to ASRT. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of 84.04% and a revenue growth -20.57% for ASRT


Ownership
Inst Owners38.74%
Ins Owners0.95%
Short Float %6.5%
Short Ratio8.83
Analysts
Analysts82
Price Target3.09 (280.87%)
EPS Next Y84.04%
Revenue Next Year-20.57%